當前位置：   首頁(yè) > 需求大廳

 >  生產(chǎn)研發(fā) 

 >  工藝技術(shù) 

需求內容：由透明質(zhì)酸均屬于多糖類(lèi)物質(zhì)，應用該原料交聯(lián)合成的水凝膠可避免異基因蛋白組分的凝膠帶來(lái)的免疫學(xué)疑慮，部分廠(chǎng)家透明質(zhì)酸凝膠產(chǎn)品吸水性強，與皮膚組織相容性好，可塑性強，可以根據不同需要塑性。 技術(shù)指標： 1. 體內停留時(shí)間可達到6個(gè)月以上 2. 有較好的細胞相容性、組織相容性 3. 可用于顏面部注射 4. 顆粒度均一，并可根據需要調節生產(chǎn)不同顆粒度的凝膠 5. 生產(chǎn)成本在200元/毫升以下 6. 1年內可獲SFDA批準用于臨床試驗（含已獲SFDA批準）   [更多]

排行世界的第五大的制藥公司尋找合作伙伴，要求提供多種大環(huán)結構藥物與合成技術(shù)，尋找有關(guān)大環(huán)領(lǐng)域的新藥發(fā)現。希望此公司提供化學(xué)詳細的3 d模型。具體請鏈接：https://www.innocentive.com/ar/challenge/9933642 The Seeker, a top-five big pharma company, is looking for collaboration partners with expertise in the area of macrocycle drug discovery. Specifically, three key areas are of interest: Chemistry partners with access to diverse macrocyclic structures & synthetic expertise In-silico chemistry partners with access to high-throughput 3-D models suitable for macrocycles In-vitro ADME experts with access to membrane systems, beyond PAMPA and Caco-2 This is an electronic Request-for-Partners (eRFP) Challenge. The Solver will write a preliminary proposal (about 2–4 pages including contact information) to be evaluated by the Seeker with a goal of establishing a collaborative partnership. Upon completion of the evaluation, the Seeker may contact selected Solvers directly to work out terms for a collaboration contract. The monetary value of the contract will vary depending on the amount of work to be delivered and the time frame agreed upon.   [更多]

甲基多巴  METHYL DOPA  CAS 555-30-6求購：原料藥 甲基多巴的商業(yè)化生產(chǎn)工藝，非專(zhuān)利網(wǎng)的文獻。有實(shí)際完整生產(chǎn)工藝的可以詳談！甲基多巴是一種抗高血壓藥，為白色或類(lèi)白色結晶性粉末；無(wú)臭。其主要是在中樞轉化成甲基去甲腎上腺素。甲基去甲腎上腺素是一種很強的中樞α2受體激動(dòng)藥。用于中、重度或惡性高血壓，還有鎮靜、降低眼壓作用。   [更多]

求購 苯磺順阿曲庫銨 原料藥 商業(yè)化生產(chǎn)工藝！Q2736068151苯磺順阿曲庫銨(cisatracurium besylate)是最新一代肌松劑，廣泛應用于氣管 插管、肝腎功能障礙、心血管手術(shù)等領(lǐng)域。苯磺酸阿曲庫銨有4個(gè)手性中心，10個(gè)同分異構體，分子中含有4個(gè)手性中心，其中2個(gè)為手性碳，2個(gè)為手性氮，順苯磺阿曲庫銨為1R,1'R,2R,2'R異構體。我方需求順苯磺阿曲庫銨大生產(chǎn)合成工藝，要求整個(gè)工藝有較好的選擇性，反應的收率和產(chǎn)品的純度較高。我司需要商業(yè)化生產(chǎn)工藝而不是 專(zhuān)利網(wǎng)文獻，需求真實(shí)有效，可提供者可私聊！   [更多]

　　富馬酸酮替芬原料工藝，要求工藝成熟，標準EP   [更多]

求五水頭孢唑林鈉原料藥合成工藝，有的請回復！   [更多]

基因治療的概念出現在幾十年前,當研究人員推測,人類(lèi)疾病可以通過(guò)精確使用一種技術(shù)引入外來(lái)DNA來(lái)解決遺傳缺陷和疾病癥狀。近年來(lái)，基因治療的進(jìn)步已經(jīng)涉足治療遺傳疾病，癌癥，神經(jīng)退行性疾病等各領(lǐng)域。遺傳性疾病如色素性視網(wǎng)膜炎等少數眼部疾病的基因也可以如此治療。公司征集一種在人類(lèi)眼部組織定性和定量(半)測量體內基因表達的方法。 具體如下https://www.innocentive.com/ar/challenge/9933643 The concept of gene therapy arose decades ago, when researchers postulated that human diseases could be treated by using a technique to introduce foreign DNA to correct genetic defects and disease phenotypes. In recent years, advances in gene therapy have been documented in the treatment of genetic disorders, cancer, and neurodegenerative diseases. Inherited diseases such as retinitis pigmentosa are among a handful of ocular diseases that are amenable to gene therapy. The Seeker desires solutions that will both qualitatively and (semi-) quantitatively measure in vivo gene expression in human ocular tissues. This Challenge requires only a written proposal. Source: InnoCentive Challenge ID: 9933643 Challenge Overview The number of clinical trials for gene therapy to treat ocular disorders is on the rise. Inherited diseases such as retinitis pigmentosa among others are thought to be good candidates for targeted treatment. Currently, there is no method in humans to determine the level or geographic location of transgene expression following administration of gene therapy for diseases of the eye, specifically the retina. The Seeker desires solutions that will both qualitatively and (semi-) quantitatively measure in vivo gene expression in human ocular tissues. Submissions to this Challenge must be received by 11:59 PM (US Eastern Time) on June 20, 2015. Late submissions will not be considered. This is a Theoretical Challenge that requires only a written proposal to be submitted. The Challenge award will be contingent upon theoretical evaluation of the proposal by the Seeker. To receive an award, Solvers will not be required to transfer their exclusive IP rights to the Seeker. Instead, Solvers will grant to the Seeker a   [更多]

控釋衣膜溶液中的丙酮回收裝置： 我公司生產(chǎn)生產(chǎn)的參透泵控釋片多以醋酸纖維素為控釋衣膜，醋酸纖維素的包衣溶液是丙酮，丙酮的沸點(diǎn)較低，在包衣的過(guò)程丙酮揮發(fā)難以回收。請設計并提供套生產(chǎn)可行的丙酮回收裝置。   [更多]

尋找一種載體某些細胞或分子如蛋白質(zhì)，DNA，RNA，和microRNA，用這些載體來(lái)制備高選擇性的靶向藥物，給藥的方法是讓藥物化合物給藥和輸送到身體的病灶而達到治療效果。具體的要求請看下面鏈接：https://www.innocentive.com/ar/challenge/9933675 AWARD: $30,000 USD | DEADLINE: 2/17/15 | ACTIVE SOLVERS: 108 | POSTED: 1/16/15 Exosomes are membrane-bound vesicles that are produced by many, if not all cell types. Exosomes are able to selectively target certain cells and deliver molecules such as proteins, DNA, RNA, and microRNA. These vesicles are thought to have great potential for targeted drug delivery. The Seeker desires innovative methods for exosome drug loading without significant disruption of the membrane components and properties of the exosome. This Challenge requires only a written proposal. Source: InnoCentive Challenge ID: 9933675 Challenge Overview Drug delivery is the method by which pharmaceutical compounds are administered and transported in the body to achieve therapeutic efficacy. Recently, exosomes have been identified as a novel method to deliver drugs in a targeted manner and their potential is derived from natural components such as specific proteins/lipids contained in the membrane of exosomes. Successful delivery of substantial amounts of therapeutic drugs using exosomes is critically dependent on a highly efficient and broadly applicable methodology for loading exosomes with the therapeutic agent, however at present no such technology is available. The Seeker is looking for one or more technologies that will facilitate exosome drug loading without significant disruption of the membrane components and properties of the exosome.   [更多]

靜脈注射的優(yōu)點(diǎn)就是快速靜脈注射藥物的分布在整個(gè)身體。通常,這些藥物總是快速代謝，快速排出，導致短期的臨床療效。大家可以從微丸持續釋放顯效得皮啟發(fā)。具體看鏈接：https://www.innocentive.com/ar/challenge/9933723 Intravenous delivery allows for the rapid distribution of injected drugs from the veins throughout the entire body. Oftentimes, these drugs are quickly metabolized and excreted resulting in short durations of clinical efficacy. Certain therapies may benefit from a bolus followed by sustained release. The Seeker wishes to identify a technology to sustain the delivery of a human high dose intravenous drug from a single injection administered over a period of 15 to 30 minutes. This Challenge requires only a written proposal. Source: InnoCentive Challenge ID: 9933723 Challenge Overview An intravenous sustained drug delivery technology is desired for a high dose drug that needs to be delivered over 8 to 10 hours. This intravenous sustained release delivery technology would allow a bolus of drug (approximately 40 to 60%) to be delivered quickly upon intravenous administration followed by the remaining dose (60 to 40%) delivered in a near zero order fashion from this intravenous administration over an 8 to 10 hour interval. This drug delivery technology needs to use materials that are already recognized as safe or can be easily qualified for parenteral administration in humans. This drug delivery technology should present no encumbrance to nurses administering the drug in a hospital setting. This technology should be amenable to delivering about 2 grams of a drug with an aqueous solubility of approximately 0.75 grams in 50 mL at 25°C and approximately 1 gram in 50 mL at 37°C during the 8 to 10 hour interval. Submissions to this Challenge must be received by 11:59 PM (US Eastern Time) on March 21, 2015. Late submissions will not be considered. This is a Theoretical Challenge that requires only a written proposal to be submitted. The Challenge award will be contingent upon theoretical evaluation of the proposal by the   [更多]